SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Supplements/Compound

PEA (Palmitoylethanolamide)

Endogenous fatty acid amide for pain and inflammation.

Immune Function

Overview

Endogenous fatty acid amide for pain and inflammation.

Natural sources
    Common forms

      Mechanism of action

      Activates PPAR-α and indirect CB receptors.

      Pathways

        Effects on the body

        Organ system effects

        Evidence-based benefits

        Reduces neuropathic pain

        Moderate evidence

        Potential side effects

        Common
        • · GI upset
        Rare
          Serious

            Drug interactions

            No notable interactions reported.

            Safety & non-supplemental interactions

            Educational summary — always confirm with your clinician or pharmacist before starting, stopping, or combining with prescription therapy.

            Avoid with these conditions
            • ·Autoimmune disease (theoretical immune activation)
            Avoid / monitor with these medications
            • ·Immunosuppressants

            Supplement interactions

            Pairs well with

            None listed.

            Avoid combining with

            No specific avoidances listed.

            Dosing & bioavailability

            Typical dose
            600 mg BID

            Where to buy

            Affiliate-style search links to reputable retailers. We don't endorse specific brands — verify third-party testing (USP, NSF, Informed Sport) before purchase.

            Compound
            PEA (Palmito…
            Amazon
            Wide selection · fast shipping
            Compound
            PEA (Palmito…
            iHerb
            Global delivery · curated brands
            Compound
            PEA (Palmito…
            Thorne
            Practitioner-grade · NSF tested

            Scientific evidence (8)

            Meta-analysisBr J Clin Pharmacol · 2016

            PEA in chronic pain

            Gabrielsson L, et al.

            12 trials

            Key findings

            Significant pain reduction across conditions.

            Open study
            Systematic reviewPubMed (NLM) · 1970

            PubMed: PEA (Palmitoylethanolamide) — Reduces neuropathic pain

            Live PubMed search

            Live results for "PEA (Palmitoylethanolamide) Reduces neuropathic pain" across the PubMed/MEDLINE peer-reviewed index.

            Key findings

            Opens current human and preclinical literature matching PEA (Palmitoylethanolamide) and "Reduces neuropathic pain". Filter by RCT, meta-analysis, or year on the results page.

            Open study
            Systematic reviewPubMed (NLM) · 1970

            PubMed: PEA (Palmitoylethanolamide) — randomized controlled trial

            Live PubMed search

            Live results for "PEA (Palmitoylethanolamide) randomized controlled trial" across the PubMed/MEDLINE peer-reviewed index.

            Key findings

            Opens current human and preclinical literature matching PEA (Palmitoylethanolamide) and "randomized controlled trial". Filter by RCT, meta-analysis, or year on the results page.

            Open study
            Systematic reviewPubMed (NLM) · 1970

            PubMed: PEA (Palmitoylethanolamide) — meta-analysis

            Live PubMed search

            Live results for "PEA (Palmitoylethanolamide) meta-analysis" across the PubMed/MEDLINE peer-reviewed index.

            Key findings

            Opens current human and preclinical literature matching PEA (Palmitoylethanolamide) and "meta-analysis". Filter by RCT, meta-analysis, or year on the results page.

            Open study
            Systematic reviewPubMed (NLM) · 1970

            PubMed: PEA (Palmitoylethanolamide) — pharmacokinetics

            Live PubMed search

            Live results for "PEA (Palmitoylethanolamide) pharmacokinetics" across the PubMed/MEDLINE peer-reviewed index.

            Key findings

            Opens current human and preclinical literature matching PEA (Palmitoylethanolamide) and "pharmacokinetics". Filter by RCT, meta-analysis, or year on the results page.

            Open study
            Systematic reviewPubMed (NLM) · 1970

            PubMed: PEA (Palmitoylethanolamide) — safety adverse events

            Live PubMed search

            Live results for "PEA (Palmitoylethanolamide) safety adverse events" across the PubMed/MEDLINE peer-reviewed index.

            Key findings

            Opens current human and preclinical literature matching PEA (Palmitoylethanolamide) and "safety adverse events". Filter by RCT, meta-analysis, or year on the results page.

            Open study
            Systematic reviewPubMed (NLM) · 1970

            PubMed: PEA (Palmitoylethanolamide) — dose response

            Live PubMed search

            Live results for "PEA (Palmitoylethanolamide) dose response" across the PubMed/MEDLINE peer-reviewed index.

            Key findings

            Opens current human and preclinical literature matching PEA (Palmitoylethanolamide) and "dose response". Filter by RCT, meta-analysis, or year on the results page.

            Open study
            Systematic reviewGoogle Scholar · 1970

            Google Scholar: PEA (Palmitoylethanolamide) — clinical evidence

            Live Scholar search

            Cross-database citation index for PEA (Palmitoylethanolamide) as it relates to "clinical evidence".

            Key findings

            Includes preprints, theses, and journal articles. Useful for tracking citation counts and follow-on work.

            Open study
            Educational use only. This profile is not medical advice. Consult a qualified healthcare professional before starting any supplement, especially if you take prescription medication or have a chronic condition.